Vascular closure devices help seal arterial punctures after a cardiovascular procedure such as angiography or angioplasty. They help stop bleeding at the puncture site by accelerating natural clotting through mechanical or biological means. The global usage of vascular closure devices has been increasing with growth in interventional cardiology and radiology procedures worldwide. Improved patient comfort, reduced hospital stay times, and lower complication rates compared to manual compression methods have made vascular closure devices an integral part of vascular access site management.

Market Dynamics:

The global vascular closure device market is growing substantially, propelled by a confluence of factors ranging from demographic shifts to technological progress. A significant contributor to this growth is the rising geriatric population which is more susceptible to cardiovascular diseases due to physiological aging. As the elderly population grows, so does the incidence of cardiovascular conditions, thereby increasing the demand for effective vascular closure devices following diagnostic and therapeutic procedures. Simultaneously, a notable shift towards minimally invasive surgeries (MIS) across the healthcare sector. MIS procedures reduce the risk of infection, shorten hospital stays, and speed up patient recovery times compared to traditional open surgeries. Vascular closure devices play a key role in these procedures by providing rapid hemostasis, reducing time to ambulation, and enhancing patient comfort.

Advancements in device technology have also been pivotal, leading to devices that offer greater efficacy and a reduced risk of post-procedure complications. Enhanced designs and materials have yielded products with improved sealing capabilities and compatibility with various anatomies and puncture sizes. On the other side of the spectrum, the high costs associated with these advanced devices can act as a barrier to their widespread adoption. The lack of reimbursement in certain healthcare systems further exacerbates this issue, making it challenging for patients to access these technologies. While existing alternatives for achieving hemostasis, such as manual compression, exist, they often come with longer recovery times and elevated risks of complications, thereby providing an opening for the adoption of advanced vascular closure devices.

The market is ripe with opportunities, especially within emerging economies that are currently witnessing increased healthcare investments and enhancements to their healthcare infrastructure. The significant potential in the ongoing development of novel devices, including those made from biodegradable materials, commonly used in complex procedures like transcatheter aortic valve replacement (TAVR).Overall, while challenges like cost and reimbursement issues persist, the benefits of vascular closure devices, including the advancements in technology and rising demands for MIS, are likely to continue to drive market growth.

For instance, in January 2021, Haemonetics Corporation, a medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, entered into a definitive agreement to acquire privately-held Cardiva Medical, Inc., a manufacturer of vascular closure systems.

Key features of the study:

• This report provides in-depth analysis of the global vascular closure device market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global vascular closure device market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Abbott, Cardiva Medical Inc., Terumo Corporation, Johnson & Johnson Services Inc., B. Braun SE, Biotronik SE & Co. KG, MicroPort Scientific Corporation, ConforMIS, Inc., Medtronic, Transluminal Technologies LLC, Cardinal Health, Teleflex Incorporated, Vasorum Ltd., Tricol Biomedical, Merit Medical Systems, Inc., Stryker
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global vascular closure device market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global vascular closure device market

Detailed Segmentation:

Global Vascular Closure Device Market

• By Product Type
• • Passive Vascular Closure Devices
  • Active Vascular Closure Devices
  • External Hemostatic Devices
• By Access
• • Femoral
  • Radial
• By Hole Size
• • Small Hole
  • Large Hole
• By End User
• • Hospitals
  • Ambulatory Surgery Centers
  • Others
• By Region
• • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Top companies in Global Vascular Closure Device Market:
• • Abbott
  • Cardiva Medical Inc.
  • Terumo Corporation
  • Johnson & Johnson Services Inc.
  • B.Braun SE
  • Biotronik SE & Co. KG
  • MicroPort Scientific Corporation
  • ConforMIS, Inc.
  • Medtronic
  • Transluminal Technologies LLC
  • Cardinal Health
  • Teleflex Incorporated
  • Vasorum Ltd.
  • Tricol Biomedical
  • Merit Medical Systems, Inc.
  • Stryker